\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ treatment\ \(1387\)\
\-\ \\ \\-chemotherapy\ \(0\)\
\-\ \\ \\-radiation\\ therapy\ \(0\)\
\-\ survival\\ rate\\ 50\\%\\ at\\ 5\\ yrs\\.\ \(0\)\
\-\ complications\ \(227\)\
\-\ \\ \\-intracranial\\ extension\\.\ \(0\)\
\-\ ct\ \(23117\)\
\-\ asymmetric\\ fullness\\ of\\ left\\ lateral\\ soft\\ tissues\\ of\\ the\\ nasopharynx\\ at\\ the\\ level\\ of\\ the\\ ptyergoid\\ plates\\.\ \(0\)\
\-\ mass\\ lesion\\ along\\ course\\ of\\ the\\ eustachian\\ tube\\ and\\ into\\ left\\ tmj\\ with\\ central\\ hypoattenuation\\ and\\ rim\\ enhancement\\ post\\ contrast\\.\ \(0\)\
\-\ soft\\ tissue\\ density\\ in\\ left\\ middle\\ ear\\ and\\ mastoid\\ air\\ cells\\.\ \(0\)\
\-\ osseous\\ erosion\\ of\\ left\\ mastoid\\ air\\ cells\\.\ \(0\)\
\-\ mr\ \(14\)\
\-\ high\\ t2\\ signal\\ abnormality\\ in\\ the\\ left\\ postero\\-lateral\\ nasopharynx\\ with\\ a\\ well\\-circumscribed\\ focus\\ measuring\\ approximately\\ 1\\.8cm\\.\\ \ \(0\)\
\-\ extension\\ along\\ the\\ approximate\\ course\\ of\\ eustachian\\ tube\\ both\\ laterally\\ and\\ superiorly\\ with\\ divergence\\ at\\ approximately\\ the\\ epitympanum\\ superiorly\\ into\\ the\\ temporal\\ bone\\ and\\ laterally\\ through\\ the\\ mastoid\\ air\\ cells\\.\\ \\ \ \(0\)\
\-\ high\\ t2\\ signal\\ abnormality\\ within\\ the\\ posterior\\ auricular\\ subcutaneous\\ soft\\ tissues\\.\\ \\ \ \(0\)\
\-\ invasion\\ of\\ the\\ signal\\ abnormalities\\ through\\ the\\ temporal\\ bones\\ and\\ into\\ the\\ posterolateral\\,\\ middle\\ cranial\\ fossa\\ with\\ left\\ temporal\\ lobe\\ involvement\\.\ \(0\)\
\-\ embryonal\\ rhabdomyosarcoma\ \(2\)\
\-\ \\ \\-botryoid\\ type\\.\ \(0\)\
\-\ differential\\-aggressive\\ pediatric\\ nasopharyngeal\\ mass\ \(0\)\
\-\ infection\ \(713\)\
\-\ neoplasm\ \(440\)\
\-\ \\ \\-rhabdomyosarcoma\ \(0\)\
\-\ concern\\ for\\ possible\\ abscess\\ of\\ middle\\ ear\\.\ \(0\)\
\-\ the\\ patient\\ was\\ originally\\ thought\\ to\\ have\\ a\\ middle\\ ear\\ infection\\ and\\ treated\\ repeatedly\\ with\\ b\\-lactam\\ and\\ fluuroquinolone\\ antibiotics\\.\\ \\ on\\ the\\ day\\ of\\ admission\\ the\\ ct\\ scan\\ was\\ thought\\ to\\ demonstrate\\ and\\ aggressive\\ infection\\ of\\ the\\ middle\\ ear\\ but\\ neoplastic\\ mass\\ was\\ not\\ ruled\\ out\\.\\ \\ a\\ biopsy\\ was\\ performed\\ demonstrating\\ botryoid\\ type\\ rhabdomyosarcoma\\ and\\ mr\\ was\\ subsequently\\ performed\\ in\\ order\\ to\\ determine\\ extent\\.\\ \\ \ \(0\)\
\-\ the\\ presence\\ of\\ intracranial\\ extension\\ resulted\\ in\\ expeditious\\ initiation\\ and\\ radiation\\ and\\ chemotherapy\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ear\\:\\ 0\\.06452640977744684\ \(0\)\
\-\ \\-high\\:\\ 0\\.06224039266978201\ \(0\)\
\-\ middle\\:\\ 0\\.059868945778590754\ \(0\)\
\-\ eustachian\\:\\ 0\\.05913338034711409\ \(0\)\
\-\ mastoid\\:\\ 0\\.05659423133167668\ \(0\)\
\-\ nasopharynx\\:\\ 0\\.04498911451954067\ \(0\)\
\-\ cells\\:\\ 0\\.0393844447603448\ \(0\)\
\-\ temporal\\:\\ 0\\.039332079053036054\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.03684433133129523\ \(0\)\
\-\ laterally\\:\\ 0\\.03670625849219424\ \(0\)\
\-\ superiorly\\:\\ 0\\.036437359489809036\ \(0\)\
\-\ \\-asymmetric\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ ptyergoid\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ \\-osseous\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ divergence\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ \\-invasion\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ \\-botryoid\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ differential\\-aggressive\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ fluuroquinolone\\:\\ 0\\.03377593265887547\ \(0\)\
\-\ air\\:\\ 0\\.03323290375347088\ \(0\)\
\-\ \\-radiation\\:\\ 0\\.031120196334891007\ \(0\)\
\-\ \\-intracranial\\:\\ 0\\.031120196334891007\ \(0\)\
\-\ epitympanum\\:\\ 0\\.031120196334891007\ \(0\)\
\-\ \\-rhabdomyosarcoma\\:\\ 0\\.031120196334891007\ \(0\)\
\-\ b\\-lactam\\:\\ 0\\.031120196334891007\ \(0\)\
\-\ botryoid\\:\\ 0\\.031120196334891007\ \(0\)\
\-\ thought\\:\\ 0\\.03013575863126534\ \(0\)\
\-\ \\-chemotherapy\\:\\ 0\\.029566690173557043\ \(0\)\
\-\ \\-soft\\:\\ 0\\.029566690173557043\ \(0\)\
\-\ expeditious\\:\\ 0\\.029566690173557043\ \(0\)\
\-\ infection\\:\\ 0\\.028551914644515022\ \(0\)\
\-\ \\-mass\\:\\ 0\\.02846446001090654\ \(0\)\
\-\ postero\\-lateral\\:\\ 0\\.02846446001090654\ \(0\)\
\-\ 1\\.8cm\\:\\ 0\\.027609503875603056\ \(0\)\
\-\ auricular\\:\\ 0\\.027609503875603056\ \(0\)\
\-\ repeatedly\\:\\ 0\\.027609503875603056\ \(0\)\
\-\ tube\\:\\ 0\\.0275906717728545\ \(0\)\
\-\ tmj\\:\\ 0\\.026910953849572577\ \(0\)\
\-\ \\-extension\\:\\ 0\\.026910953849572577\ \(0\)\
\-\ tissues\\:\\ 0\\.026875484494753205\ \(0\)\
\-\ signal\\:\\ 0\\.02589740609508941\ \(0\)\
\-\ initiation\\:\\ 0\\.025357447688238614\ \(0\)\
\-\ hypoattenuation\\:\\ 0\\.02495376755161859\ \(0\)\
\-\ course\\:\\ 0\\.024709053206556638\ \(0\)\
\-\ approximate\\:\\ 0\\.02425521752558811\ \(0\)\
\-\ abnormality\\:\\ 0\\.024157532136632583\ \(0\)\
\-\ extension\\:\\ 0\\.023374155717867075\ \(0\)\
\-\ into\\:\\ 0\\.023371567447812724\ \(0\)\
\-\ nasopharyngeal\\:\\ 0\\.02270171136425415\ \(0\)\
\-\ embryonal\\:\\ 0\\.022111095732732088\ \(0\)\
\-\ type\\:\\ 0\\.022073748876221534\ \(0\)\
\-\ left\\:\\ 0\\.02197943147753827\ \(0\)\
\-\ plates\\:\\ 0\\.02193285812493556\ \(0\)\
\-\ along\\:\\ 0\\.021640259592785562\ \(0\)\
\-\ mr\\:\\ 0\\.020806126221811754\ \(0\)\
\-\ yrs\\:\\ 0\\.020744525066300163\ \(0\)\
\-\ approximately\\:\\ 0\\.020259140433376115\ \(0\)\
\-\ was\\:\\ 0\\.018932519582637676\ \(0\)\
\-\ fullness\\:\\ 0\\.01871146663311177\ \(0\)\
\-\ through\\:\\ 0\\.01859737178866566\ \(0\)\
\-\ posterolateral\\:\\ 0\\.018564086246798377\ \(0\)\
\-\ t2\\:\\ 0\\.01853324727011764\ \(0\)\
\-\ originally\\:\\ 0\\.01849246887893572\ \(0\)\
\-\ resulted\\:\\ 0\\.01849246887893572\ \(0\)\
\-\ performed\\:\\ 0\\.018257305220132712\ \(0\)\
\-\ ruled\\:\\ 0\\.018218679744904518\ \(0\)\
\-\ survival\\:\\ 0\\.017553302373062216\ \(0\)\
\-\ well\\-circumscribed\\:\\ 0\\.017337390738766695\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.017034753147507572\ \(0\)\
\-\ neoplastic\\:\\ 0\\.016754280335157783\ \(0\)\
\-\ determine\\:\\ 0\\.016578092161817465\ \(0\)\
\-\ erosion\\:\\ 0\\.016535282580981737\ \(0\)\
\-\ order\\:\\ 0\\.016409651075912805\ \(0\)\
\-\ concern\\:\\ 0\\.01628800855363472\ \(0\)\
\-\ extent\\:\\ 0\\.016248304388747567\ \(0\)\
\-\ aggressive\\:\\ 0\\.016018350328493726\ \(0\)\
\-\ soft\\:\\ 0\\.015945798957804982\ \(0\)\
\-\ pediatric\\:\\ 0\\.015766429341663148\ \(0\)\
\-\ subsequently\\:\\ 0\\.014842436786809172\ \(0\)\
\-\ focus\\:\\ 0\\.014707987285616566\ \(0\)\
\-\ admission\\:\\ 0\\.01442782535140598\ \(0\)\
\-\ cranial\\:\\ 0\\.014236214544606511\ \(0\)\
\-\ demonstrating\\:\\ 0\\.014212923180329186\ \(0\)\
\-\ rim\\:\\ 0\\.013858319512263113\ \(0\)\
\-\ intracranial\\:\\ 0\\.013837209719883918\ \(0\)\
\-\ bones\\:\\ 0\\.013816215598180373\ \(0\)\
\-\ fossa\\:\\ 0\\.013344059887743788\ \(0\)\
\-\ at\\:\\ 0\\.013307622446340608\ \(0\)\
\-\ measuring\\:\\ 0\\.013093316944248066\ \(0\)\
\-\ complications\\:\\ 0\\.012973842126482978\ \(0\)\
\-\ rate\\:\\ 0\\.012761385020980242\ \(0\)\
\-\ 50\\:\\ 0\\.012455931098252125\ \(0\)\
\-\ antibiotics\\:\\ 0\\.01229776382249234\ \(0\)\
\-\ abnormalities\\:\\ 0\\.012025918090797763\ \(0\)\
\-\ involvement\\:\\ 0\\.011999764967922667\ \(0\)\
\-\ presence\\:\\ 0\\.01188423608604264\ \(0\)\
\-\ n\\/a\\:\\ 0\\.011859029300226384\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.011735424464141246\ \(0\)\
\-\ biopsy\\:\\ 0\\.011615682918148507\ \(0\)\
\-\ neoplasm\\:\\ 0\\.011150025195064858\ \(0\)\
\-\ possible\\:\\ 0\\.011026751796490698\ \(0\)\
\-\ out\\:\\ 0\\.010820129796392781\ \(0\)\
\-\ central\\:\\ 0\\.010772533934329346\ \(0\)\
\-\ density\\:\\ 0\\.010772533934329346\ \(0\)\
\-\ radiation\\:\\ 0\\.010744257661158376\ \(0\)\
\-\ day\\:\\ 0\\.010394482104800496\ \(0\)\
\-\ abscess\\:\\ 0\\.010351863004345851\ \(0\)\
\-\ post\\:\\ 0\\.01030971277039193\ \(0\)\
\-\ treated\\:\\ 0\\.009800194774267659\ \(0\)\
\-\ 5\\:\\ 0\\.009579158706682618\ \(0\)\
\-\ the\\:\\ 0\\.009534433427836261\ \(0\)\
\-\ level\\:\\ 0\\.009436356427766022\ \(0\)\
\-\ scan\\:\\ 0\\.00916579103614168\ \(0\)\
\-\ ct\\:\\ 0\\.009159414968521401\ \(0\)\
\-\ mass\\:\\ 0\\.009106980896149919\ \(0\)\
\-\ lobe\\:\\ 0\\.008809675662542276\ \(0\)\
\-\ enhancement\\:\\ 0\\.008775819027291324\ \(0\)\
\-\ therapy\\:\\ 0\\.00875341301241614\ \(0\)\
\-\ both\\:\\ 0\\.008360919504544526\ \(0\)\
\-\ and\\:\\ 0\\.00827627612561924\ \(0\)\
\-\ bone\\:\\ 0\\.008135765063064635\ \(0\)\
\-\ tissue\\:\\ 0\\.007760234438515684\ \(0\)\
\-\ \\%\\:\\ 0\\.00763724533849045\ \(0\)\
\-\ posterior\\:\\ 0\\.0075465078494346685\ \(0\)\
\-\ demonstrate\\:\\ 0\\.007534299392080615\ \(0\)\
\-\ contrast\\:\\ 0\\.007328642478191208\ \(0\)\
\-\ have\\:\\ 0\\.007089801066532919\ \(0\)\
\-\ lateral\\:\\ 0\\.007075356496645787\ \(0\)\
\-\ but\\:\\ 0\\.00698277126832773\ \(0\)\
\-\ lesion\\:\\ 0\\.0066687939693504\ \(0\)\
\-\ treatment\\:\\ 0\\.00662688490268539\ \(0\)\
\-\ in\\:\\ 0\\.006458195097934941\ \(0\)\
\-\ within\\:\\ 0\\.006245714208375791\ \(0\)\
\-\ of\\:\\ 0\\.004910121872712156\ \(0\)\
\-\ to\\:\\ 0\\.004908828832678003\ \(0\)\
\-\ not\\:\\ 0\\.004731106021999752\ \(0\)\
\-\ a\\:\\ 0\\.00455861841170806\ \(0\)\
\-\ patient\\:\\ 0\\.003281961421135586\ \(0\)\
\-\ for\\:\\ 0\\.0027935178108916287\ \(0\)\
\-\ on\\:\\ 0\\.0027735287830093027\ \(0\)\
\-\ with\\:\\ 0\\.002241459312066853\ \(0\)\
\-\ \\.\\:\\ 0\\.0021762167722511124\ \(0\)\
\-\ \\,\\:\\ 0\\.001037203316158189\ \(0\)\
